Works by Suttner, Leah H.

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3

By:

• Stathis, Anastasios;
• Tolcher, Anthony W.;
• Wang, Judy S.;
• Renouf, Daniel J.;
• Chen, Lin-Chi;
• Suttner, Leah H.;
• Freshwater, Tomoko;
• Webber, Andrea L.;
• Nayak, Tapan;
• Siu, Lillian L.

Publication type:

Article